SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation has launched a new platform for gene expression analysis that runs gold standard TaqMan® assays on nanofluidic chips known as BioMark™ dynamic arrays. The BioMark system delivers radically higher throughput than 384-microwell plate systems, and at greatly reduced running costs. With the system’s clear-cut advantages, the Company expects to take a significant share of the $1 billion real-time qPCR market, which experts estimate to be growing at 20 to 25 percent annually.
